Metraipolis › archive › dc_39797f100a4c

Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity — Europe PMC PMID:41487530

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41487530
DOI
10.3389/fphar.2025.1698727
License (as archived)
solo-consultazione
Archived
2026-11-07T13:20:02.334Z
SHA-256 of the archived text
6c5c9be544811eb589c68bfafa4813aa5344044221d3cc5d55dc87e261b0d6dc
Stable URL of this page
https://metraipolis.com/documento/dc_39797f100a4c

How to cite

Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity — Europe PMC PMID:41487530 — Europe PMC (en), https://europepmc.org/article/MED/41487530 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39797f100a4c (Metraipolis archive dc_39797f100a4c, sha256 6c5c9be544811eb589c68bfafa4813aa5344044221d3cc5d55dc87e261b0d6dc)
BibTeX
@misc{dc39797f100a4c,
  title = {Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity — Europe PMC PMID:41487530},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41487530},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39797f100a4c; sha256 6c5c9be544811eb589c68bfafa4813aa5344044221d3cc5d55dc87e261b0d6dc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41487530. Agents can read the archived copy with the MCP tool read_document.